Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small cell lung cancer.
Loading...
Date
2015-04
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Aberrant increased expression and activation of receptor tyrosine kinases occur frequently in
human carcinomas. Several small molecules targeting receptor tyrosine kinases, which have
crucial roles in the growth factor signaling that promote tumor progression in various
malignancies, including non-small cell lung cancer (NSCLC), are currently in clinical
development. Therapeutic strategies include inhibition of growth factor tyrosine kinase
function. Drugs of this type include those that target the epidermal growth factor receptor
tyrosine kinase, those that target vascular endothelial growth factor receptors tyrosine kinase
and those that target anaplastic lymphoma receptor tyrosine kinase. In this review we first
discuss the role of receptor tyrosine kinases in human malignancies, and focus on discussing
the potential use of epidermal growth factor receptor tyrosine kinase inhibitors and the
vascular endothelial growth factor receptors tyrosine kinase inhibitors in NSCLC. In addition,
we discuss the contribution of growth factor receptor tyrosine kinase inhibitors to the
clinically observed resistance, and toxicity.
Description
Keywords
NSCLC (Non-small cell lung cancer), tyrosine kinase inhibitor, EGFR (endothelial growth factor receptor), VEGFR (vascular endothelial growth factor receptor)
Citation
Lawaly Maman Manzo1,3, Moudirat Lawaly2 , Lui YU1. Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small cell lung cancer. Indian Journal of Pharmaceutical & Biological Research. 2015 Apr-Jun; 3(2): 81-87.